Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 12:10:930.
doi: 10.3389/fonc.2020.00930. eCollection 2020.

Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors

Affiliations
Review

Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors

Lachlan McDowell et al. Front Oncol. .

Abstract

Concerted research efforts over the last three decades have resulted in improved survival and outcomes for patients diagnosed with nasopharyngeal carcinoma (NPC). The evolution of radiotherapy techniques has facilitated improved dose delivery to target volumes while reducing dose to the surrounding normal tissue, improving both disease control and quality of life (QoL). In parallel, clinical trials focusing on determining the optimal systemic therapy to use in conjunction with radiotherapy have been largely successful, resulting in improved locoregional, and distant control. As a consequence, neoadjuvant chemotherapy (NACT) prior to definitive chemoradiotherapy has recently emerged as the preferred standard for patients with locally advanced NPC. Two of the major challenges in interpreting toxicity and QoL data from the published literature have been the reliance on: (1) clinician rather than patient reported outcomes; and (2) reporting statistical rather than clinical meaningful differences in measures. Despite the lower rates of toxicity that have been achieved with highly conformal radiotherapy techniques, survivors remain at moderate risk of persistent and long-lasting treatment effects, and the development of late radiation toxicities such as hearing loss, cranial neuropathies and cognitive impairment many years after successful treatment can herald a significant decline in QoL. Future approaches to reduce long-term toxicity will rely on: (1) identifying individual patients most likely to benefit from NACT; (2) development of response-adapted radiation strategies following NACT; and (3) anticipated further dose reductions to organs at risk with proton and particle therapy. With increasing numbers of survivors, many in the prime of their adult life, research to identify, and strategies to address the unmet needs of NPC survivors are required. This contemporary review will summarize our current knowledge of long-term toxicity, QoL and unmet needs of this survivorship group.

Keywords: chemotherapy; nasopharyngeal carcinoma; quality of life; radiotherapy; survivorship; toxicity; unmet needs.

PubMed Disclaimer

References

    1. Ng WT, Lee MC, Hung WM, Choi CW, Lee KC, Chan OS, et al. . Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. (2011) 79:420–8. 10.1016/j.ijrobp.2009.11.024 - DOI - PubMed
    1. Lee JY, Sun JM, Oh DR, Lim SH, Goo J, Lee SH, et al. . Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: a multicenter randomized phase II trial (KCSG-HN10-02). Radiother Oncol. (2016) 118:244–50. 10.1016/j.radonc.2015.11.030 - DOI - PubMed
    1. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. . Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. (1998) 16:1310–7. 10.1200/JCO.1998.16.4.1310 - DOI - PubMed
    1. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. . Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American joint committee on cancer/International union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. (2005) 23:6730–8. 10.1200/JCO.2005.16.790 - DOI - PubMed
    1. Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, et al. . Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. (2011) 103:1761–70. 10.1093/jnci/djr432 - DOI - PubMed